Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells
- PMID: 15316930
- DOI: 10.1002/jcp.20153
Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells
Abstract
The purpose of this study was to evaluate the possible involvement of the phosphoinositide 3-kinase (PI3K)/Akt survival pathway in determining resistance to arsenic trioxide (As2O3)-induced apoptosis. We employed a HL60 cell clone (HL60AR) with a constitutively active PI3K/Akt survival pathway, as well as U937 and K562 cells. In addition, we used parental (PT) HL60 cells overexpressing a constitutively active Akt. Selective pharmacological inhibitors of the PI3K/Akt axis (LY294002, wortmannin) were employed to influence the sensitivity to As2O3. While HL60PT cells were sensitive to 2.5 microM As2O3 and died of apoptosis, HL60AR cells were resistant up to 5 microM As2O3. Treatment with either LY294002 or wortmannin lowered resistance of HL60AR cells to As2O3. Also in U937 and K562 cells, inhibitors of the PI3K/Akt axis caused a decrease in As2O3 resistance. Overexpression of constitutively active Akt in HL60PT cells caused the induction of resistance to 2.5 microM As2O3. Conversely, forced expression of a dominant negative Akt in HL60AR cells resulted in a decrease in As2O3 resistance. Moreover, HL60 cell resistance to 2.5 microM As2O3 could be significantly reduced by incubation with SN50, a peptide inhibitor selective for the NF-kappaB transcription factor. Taken together our findings suggest that a constitutive activation of the PI3K/Akt pathway, which is increasingly detected in some types of acute myeloid leukemia, may contribute to As2O3 resistance, most likely through NF-kappaB activation. Selective pharmacological inhibitors of this survival pathway, as well as of NF-kappaB, might be usefully employed in the future to reverse resistance to this treatment.
2004 Wiley-Liss, Inc.
Similar articles
-
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.Leukemia. 2003 Sep;17(9):1794-805. doi: 10.1038/sj.leu.2403044. Leukemia. 2003. PMID: 12970779
-
Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.Blood. 2005 May 15;105(10):4013-20. doi: 10.1182/blood-2004-07-2802. Epub 2005 Jan 21. Blood. 2005. PMID: 15665116
-
Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.Leukemia. 2003 Feb;17(2):379-89. doi: 10.1038/sj.leu.2402793. Leukemia. 2003. PMID: 12592338
-
Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.Vitam Horm. 2004;67:409-26. doi: 10.1016/S0083-6729(04)67021-X. Vitam Horm. 2004. PMID: 15110188 Review.
-
The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.Biochim Biophys Acta. 2000 Feb 14;1470(1):M21-35. doi: 10.1016/s0304-419x(99)00032-3. Biochim Biophys Acta. 2000. PMID: 10656987 Review. No abstract available.
Cited by
-
Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation of SESN2.Oncotarget. 2018 Mar 23;9(22):16028-16042. doi: 10.18632/oncotarget.24678. eCollection 2018 Mar 23. Oncotarget. 2018. PMID: 29662624 Free PMC article.
-
Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.Leukemia. 2014 Apr;28(4):761-9. doi: 10.1038/leu.2013.245. Epub 2013 Aug 20. Leukemia. 2014. PMID: 23958920
-
Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia.Oncol Lett. 2016 Nov;12(5):3755-3762. doi: 10.3892/ol.2016.5162. Epub 2016 Sep 21. Oncol Lett. 2016. PMID: 27895727 Free PMC article.
-
MicroRNA-524 promotes cell proliferation by down-regulating PTEN expression in osteosarcoma.Cancer Cell Int. 2018 Aug 13;18:114. doi: 10.1186/s12935-018-0612-1. eCollection 2018. Cancer Cell Int. 2018. PMID: 30123092 Free PMC article.
-
Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology.Front Pharmacol. 2018 Feb 27;9:143. doi: 10.3389/fphar.2018.00143. eCollection 2018. Front Pharmacol. 2018. PMID: 29535630 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous